Need Help?

Transcriptome Sequencing Data of High Grade Serous Ovarian Cancer

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 10 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001006456	RNA sequencing data of over 200 HGSOC samples at diagnosis, after chemotherapy and during progression.	unspecified	212

Publications	Citations
Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. Jukonen J, Moyano-Galceran L, Höpfner K, Pietilä EA, Lehtinen L, Huhtinen K, Gucciardo E, Hynninen J, Hietanen S, Grénman S, Ojala PM, Carpén O, Lehti K. Sci Rep 11: 2021 8856	13
Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Pietilä EA, Gonzalez-Molina J, Moyano-Galceran L, Jamalzadeh S, Zhang K, Lehtinen L, Turunen SP, Martins TA, Gultekin O, Lamminen T, Kaipio K, Joneborg U, Hynninen J, Hietanen S, Grénman S, Lehtonen R, Hautaniemi S, Carpén O, Carlson JW, Lehti K. Nat Commun 12: 2021 3904	121
Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Zhang K, Erkan EP, Jamalzadeh S, Dai J, Andersson N, Kaipio K, Lamminen T, Mansuri N, Huhtinen K, Carpén O, Hietanen S, Oikkonen J, Hynninen J, Virtanen A, Häkkinen A, Hautaniemi S, Vähärautio A. Sci Adv 8: 2022 eabm1831	120
Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Roering P, Siddiqui A, Heuser VD, Potdar S, Mikkonen P, Oikkonen J, Li Y, Pikkusaari S, Wennerberg K, Hynninen J, Grenman S, Huhtinen K, Auranen A, Carpén O, Kaipio K. Front Oncol 12: 2022 954430	12
A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, Oikkonen J, Bulanova D, Pietras EJ, Voßgröne K, Chen YJ, Erkan EP, Dai J, Lundgren A, Grønning Høg MK, Larsen IM, Lamminen T, Kaipio K, Huvila J, Virtanen A, Engelholm L, Christiansen P, Santoni-Rugiu E, Huhtinen K, Carpén O, Hynninen J, Hautaniemi S, Vähärautio A, Wennerberg K. Dev Cell 58: 2023 1106-1121.e7	72
Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma. Jamalzadeh S, Dai J, Lavikka K, Li Y, Jiang J, Huhtinen K, Virtanen A, Oikkonen J, Hietanen S, Hynninen J, Vähärautio A, Häkkinen A, Hautaniemi S. BMC Cancer 24: 2024 173	8
Locus-specific LINE-1 expression in clinical ovarian cancer specimens at the single-cell level. Perkiö A, Pradhan B, Genc F, Pirttikoski A, Pikkusaari S, Erkan EP, Falco MM, Huhtinen K, Narva S, Hynninen J, Kauppi L, Vähärautio A. Sci Rep 14: 2024 4322	1
In silico RNA isoform screening to identify potential cancer driver exons with therapeutic applications. Anglada-Girotto M, Ciampi L, Bonnal S, Head SA, Miravet-Verde S, Serrano L. Nat Commun 15: 2024 7039	5
Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer. Micoli G, Lavikka K, Li Y, Pirttikoski A, Afenteva D, Senkowski W, Marchi G, Vähärautio A, Muranen TA, Joutsiniemi T, Hietanen S, Virtanen A, Wennerberg K, Hynninen J, Oikkonen J, Hautaniemi S. Cancer Discov 15: 2025 2262-2277	0
Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer. Afenteva D, Yu R, Rajavuori A, Salvadores M, Launonen IM, Lavikka K, Zhang K, Pirttikoski A, Marchi G, Jamalzadeh S, Isoviita VM, Li Y, Micoli G, Erkan EP, Falco MM, Ungureanu D, Lahtinen A, Oikkonen J, Hietanen S, Vähärautio A, Sur I, Virtanen A, Färkkilä A, Hynninen J, Muranen TA, Taipale J, Hautaniemi S. Cell Rep Med 6: 2025 102316	0